Last reviewed · How we verify
Zevalin
Zevalin is a Small molecule drug developed by Spectrum Pharmaceuticals, Inc. It is currently in discontinued development for Follicular non-Hodgkin's lymphoma. Also known as: Ibritumomab tiuxetan, 90Y-ibritumomab tiuxetan, IDEC-Y2B8, Ibritumomab Tiuxetan.
At a glance
| Generic name | Zevalin |
|---|---|
| Also known as | Ibritumomab tiuxetan, 90Y-ibritumomab tiuxetan, IDEC-Y2B8, Ibritumomab Tiuxetan, 90Y-Ibritumomab-Tiuxetan |
| Sponsor | Spectrum Pharmaceuticals, Inc |
| Target | B-lymphocyte antigen CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Approved indications
- Follicular non-Hodgkin's lymphoma
Common side effects
Key clinical trials
- A Phase I Trial Combining IDEC-Y2B8 And High-Dose Beam Chemotherapy With Hematopoietic Progenitor Cell Transplant In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma (Phase 1)
- A Phase 2 Exploratory Study of Intravenous QUZYTTIR™ (Cetirizine Hydrochloride Injection) Versus Intravenous Diphenhydramine in the Prevention of Hypersensitivity Infusion Reactions (Phase 2)
- A Phase II Study of R-FND, Followed by Zevalin Radioimmunotherapy, and Subsequent Maintenance Rituximab for Advanced Stage Follicular Lymphoma With High-Risk Features (Phase 2)
- SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring A (Phase 3)
- A Phase II Trial of High-Dose 90Y-Ibritumomab Tiuxetan (Anti-CD20) Followed by Fludarabine and Low-Dose Total Body Irradiation and HLA-Matched Allogeneic Hematopoietic Transplantation for Patients Wit (Phase 2)
- A Phase II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II (Phase 2)
- Phase II Trial of Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in the Treatment of Patients With Relapsed/Refractory Intermediate Grade B-Cell Lymphoma (Phase 2)
- Phase II Trial of Rituximab and Short Duration Chemotherapy Followed by Zevalin as First-Line Treatment for Patients With Low Grade Follicular Non-Hodgkin's Lymphoma (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zevalin CI brief — competitive landscape report
- Zevalin updates RSS · CI watch RSS
- Spectrum Pharmaceuticals, Inc portfolio CI
Frequently asked questions about Zevalin
What is Zevalin?
Zevalin is a Small molecule drug developed by Spectrum Pharmaceuticals, Inc, indicated for Follicular non-Hodgkin's lymphoma.
What is Zevalin used for?
Zevalin is indicated for Follicular non-Hodgkin's lymphoma.
Who makes Zevalin?
Zevalin is developed by Spectrum Pharmaceuticals, Inc (see full Spectrum Pharmaceuticals, Inc pipeline at /company/spectrum-pharmaceuticals-inc).
Is Zevalin also known as anything else?
Zevalin is also known as Ibritumomab tiuxetan, 90Y-ibritumomab tiuxetan, IDEC-Y2B8, Ibritumomab Tiuxetan, 90Y-Ibritumomab-Tiuxetan.
What development phase is Zevalin in?
Zevalin is in discontinued.
What does Zevalin target?
Zevalin targets B-lymphocyte antigen CD20.
Related
- Target: All drugs targeting B-lymphocyte antigen CD20
- Manufacturer: Spectrum Pharmaceuticals, Inc — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Follicular non-Hodgkin's lymphoma
- Also known as: Ibritumomab tiuxetan, 90Y-ibritumomab tiuxetan, IDEC-Y2B8, Ibritumomab Tiuxetan, 90Y-Ibritumomab-Tiuxetan